Latest news
Logging on for EPA Congress 2021
Posted on March 18, 2021In just a few weeks the Maverex team will be logging on to this year’s World EPA Congress, which is taking place virtually in place of the annual World Pharma Pricing, Evidence and Market Access Congress. We are still looking forward to the day when physical conferences come back and we can meet up …
Read more
Doing good for our city and ourselves
Posted on March 3, 2021Our company success is thanks to our people, which is why we’re supporting our team to feel better and do better during the ongoing COVID-19 pandemic. Knowing how well a bit of fresh air and exercise can do for our bodies and minds, our team committed to getting outside and walking, running or cycling …
Read more
Reflections on the past year
Posted on February 9, 2021Although 2020 did not turn out as any of us had planned, looking back there was a lot for us to be grateful for. In the face of a global pandemic and the accompanying restrictions, we are grateful for the continued trust of our valued clients and the rewarding and diverse projects. We are also …
Read more
Maverex posters receive special recognition at ISPOR Europe 2020
Posted on November 11, 2020Two Maverex posters have received special recognition which puts them in the top 10% of all submitted abstracts to ISPOR Europe 2020 based on scores of scientific merit. The criteria for the abstract review scores includes clearly stated objectives and research questions, appropriate and transparent research design, discussion of implication of findings, meeting of …
Read more
New study from Maverex on the risk of stroke and myocardial infarction in systemic lupus erythematosus patients
Posted on September 21, 2020Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis developed with our partners at AstraZeneca, is a systematic review of the risk of stroke and myocardial infarction (MI) in adult patients with systemic lupus erythematosus (SLE), a chronic autoimmune disorder associated with increased comorbidities. Epidemiological studies have suggested that patients …
Read more
New Maverex cost-consequence analysis of triple-chamber-bag parenteral nutrition in preterm neonates
Posted on September 21, 2020In Cost-Consequences Analysis of Increased Utilization of Triple-Chamber-Bag Parenteral Nutrition in Preterm Neonates in Seven European Countries, alongside our partners at Baxter Healthcare, we assessed national-level impacts of a 10-percentage point increase in use of industry-prepared three-chamber bags (3CBs) on clinical outcomes, healthcare resources, and hospital budgets across seven countries: Belgium, France, Germany, Italy, …
Read more
We’re going to Virtual PPMA 2020
Posted on September 19, 2020After a truly exciting time in Amsterdam last year for World Pharma Pricing, Evidence and Market Access Congress, the Maverex team is looking forward to this year’s PPMA virtual congress. Although this year’s congress will be virtual, we’ve lined up plenty of interesting talks and we’re still looking forward to networking with others who are …
Read more
Maverex Posters at ISPOR Europe 2020
Posted on September 4, 2020ISPOR Europe is one of our favourite fixtures on the Maverex calendar. Although this year will be slightly different and we’re disappointed to not be flying out to Milan, we’re still looking forward to logging on to the virtual conference from the comfort of the Maverex office and our own homes. This year, ISPOR …
Read more
Maverex celebrates its women-owned business status
Posted on June 9, 2020At the end of May 2020, Maverex was formally recognised by WEConnect International, a not-for-profit organisation working to connect women-owned and controlled businesses globally. Maverex was awarded with a certification for Women’s Business Enterprise; acknowledging Maverex not only as a women-owned company, but as also wanting to do business with others who are committed …
Read more
New publication from Maverex on COPD
Posted on December 9, 2019New publication from Maverex – Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review – in Respiratory Research We are delighted to announce that our latest publication, a systematic review of the safety and efficacy of single-inhaler triple therapies for chronic obstructive pulmonary disorder (COPD), is now available at Respiratory …
Read more